Stay updated on Talazoparib in BRCA+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Talazoparib in BRCA+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Talazoparib in BRCA+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-29T15:29:43.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A site-wide notice about NIH’s terminology transition appears above the ClinicalTrials.gov error page.
    Difference
    1%
    Check dated 2026-10-22T15:41:01.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer site revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-15T15:29:02.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T15:28:04.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error with a minimal header and a Home link, replacing the previous EMBRACA trial details.
    Difference
    16%
    Check dated 2026-09-24T19:42:37.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.6 to v3.7.0, indicating a newer site build. This reflects an underlying update to the page's code or assets rather than changes to study content.
    Difference
    0.0%
    Check dated 2026-09-17T20:48:39.000Z thumbnail image

Stay in the know with updates to Talazoparib in BRCA+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Talazoparib in BRCA+ Breast Cancer Clinical Trial page.